Predict your next investment

Elucid company logo

See what CB Insights has to offer

Founded Year



Series A | Alive

Total Raised


Last Raised

$8M | 8 mos ago

Mosaic Score

+30 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About Elucid

Elucid is a medical technology company leveraging machine intelligence to improve the accuracy, experience, and cost-effectiveness of vascular diagnostic imaging. Its product, ElucidVivo, is an FDA-cleared & CE-marked, histology-validated, non-invasive image analysis software for evaluating CTAs to provide multi-dimensional visualization, structural measurements, and plaque composition to inform risk of an event (heart attack or stroke) and personalized treatment selection.

Elucid Headquarter Location

2 Park Plaza Suite 305

Boston, Massachusetts, 02116,

United States


Latest Elucid News

Elucid Announces American Medical Association (AMA) Instates CPT Code For Lipid-Rich Necrotic Core Quantification To Assess Atherosclerotic Plaque Stability

Dec 23, 2021

Share Quantification of the structure and composition of the vessel wall and assessment of lipid-rich necrotic core plaque  Elucid, a Boston-based medical technology company harnessing scientific imaging and artificial intelligence to enable the precise diagnosis and treatment of the world’s leading cause of death announced a new CPT code unique to its Plaque IQ technology for CT angiography. Plaque composition, specifically lipid-rich necrotic core, has been identified as a major contributor to heart attacks and strokes. A new multicenter study published in the Journal of Vascular Surgery this month by Brajesh Lal, MD, et al utilizing Elucid’s software concluded “a composite of plaque geometry, plaque tissue composition, patient demographics, and clinical information predicted for major adverse neurologic events better than did the traditionally used degree of stenosis alone for those with carotid atherosclerosis.” The ElucidVivo software demonstrated a 40% improvement in predictive accuracy for these events, primarily stroke. Related Posts There is now an abundance of published literature on atherosclerosis which has long defined lipid-rich necrotic core as the major culprit for cardiovascular disease progression that leads to myocardial ischemia and acute events. “Obtaining reimbursement for providers to identify key biomarkers of arterial narrowing and plaque stability will advance the field of cardiovascular medicine and enable clinicians to intercept the disease earlier,” said Blake Richards , Elucid CEO, “Elucid’s mission is to measure flow limitation in the arteries that leads to chest pain and identify plaques that are vulnerable to rupture. Characterizing unstable plaque specifically is the key to reducing heart attacks, personalizing treatment, and restoring better quality of life.” CPT Category III codes are a set of temporary codes that allow data collection for emerging technologies, services, procedures, and service paradigms. These codes are intended to be used for data collection to substantiate widespread usage or to provide documentation for the Food and Drug Administration (FDA) approval process. Providers who utilize CTA can use this new code to track usage, which is the first step in achieving reimbursement for this important assessment

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Elucid

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Elucid in 1 CB Insights research brief, most recently on Jun 25, 2021.

Expert Collections containing Elucid

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Elucid is included in 5 Expert Collections, including Health Monitoring & Diagnostics.


Health Monitoring & Diagnostics

2,707 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,213 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Digital Health

12,248 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Medical Devices

3,286 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)


Digital Health 150

150 items

The winners of the third annual CB Insights Digital Health 150.

Elucid Patents

Elucid has filed 16 patents.

The 3 most popular patent topics include:

  • Medical imaging
  • Magnetic resonance imaging
  • Neuroimaging
patents chart

Application Date

Grant Date


Related Topics




Medical imaging, Magnetic resonance imaging, Medical terminology, Transcription factors, Neuroimaging


Application Date


Grant Date



Related Topics

Medical imaging, Magnetic resonance imaging, Medical terminology, Transcription factors, Neuroimaging



Elucid Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Elucid Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.